Key facts
- It has raised $43.8M; the latest was Later Stage VC ($27.0M) in Nov 2024.
- Notable investors include K5 Global, Collaborative Fund, Western Technology Investment, Gates Foundation, Argonautic Ventures — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for One.bio
- ·The full record, as it builds
Funding rounds
No funding rounds for One.bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About One.bio
Developer of naturally-derived oligosaccharides designed for food, agriculture, and biopharmaceutical applications. The company uses proprietary technology to create novel oligosaccharides from natural products, with a focus on producing ingredients that beneficially modulate the microbiome and immune function, enabling clients to access novel prebiotics, symbiotic, and immunomodulatory therapies for human and animal health.
- Sector
- Healthcare
- HQ
- Davis, CA, United States
- Founded
- 2019
- Employees
- 42
- Website
- one.bio/
- Ownership
- Privately Held (backing)
One.bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in One.bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on One.bio in its N-PORT filings yet. We sweep new filings monthly.